Supplementary Figure 1

A

Tumor Genotypes n=82

- 43% A (n=35)
- 23% B (n=8)
- 16% C (n=13)
- 8% D (n=19)
- 10% E (n=7)

B

Non Tumor Genotypes n=80

- 40% A (n=32)
- 15% B (n=10)
- 12% C (n=8)
- 23% D (n=18)
- 10% E (n=12)
Supplementary Figure 3

**Disease specific survival**

**HBV+**

- **Hotspot**
- **Non Hotspot**
- **WT**

- **P = 0.06**

**Numbers at risk**

<table>
<thead>
<tr>
<th></th>
<th>Hotspot</th>
<th>Non Hotspot</th>
<th>WT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>0</strong></td>
<td>13</td>
<td>18</td>
<td>36</td>
</tr>
<tr>
<td><strong>20</strong></td>
<td>8</td>
<td>11</td>
<td>24</td>
</tr>
<tr>
<td><strong>40</strong></td>
<td>5</td>
<td>7</td>
<td>19</td>
</tr>
<tr>
<td><strong>60</strong></td>
<td>3</td>
<td>3</td>
<td>12</td>
</tr>
</tbody>
</table>

**Disease specific survival**

**all patients**

- **Hotspot**
- **Non Hotspot**
- **WT**

- **P = ns**

**Numbers at risk**

<table>
<thead>
<tr>
<th></th>
<th>Hotspot</th>
<th>Non Hotspot</th>
<th>WT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>0</strong></td>
<td>13</td>
<td>34</td>
<td>107</td>
</tr>
<tr>
<td><strong>20</strong></td>
<td>8</td>
<td>22</td>
<td>73</td>
</tr>
<tr>
<td><strong>40</strong></td>
<td>5</td>
<td>12</td>
<td>41</td>
</tr>
<tr>
<td><strong>60</strong></td>
<td>3</td>
<td>6</td>
<td>25</td>
</tr>
</tbody>
</table>
Supplementary Figure 4

A) Survival of HBV+ HCC with AFP <20 ng/ml

<table>
<thead>
<tr>
<th>Numbers at risk</th>
<th>Time</th>
<th>Percent survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPS3 Mutated</td>
<td>24</td>
<td>100</td>
</tr>
<tr>
<td>TPS3 Wild-type</td>
<td>14</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>20</td>
</tr>
</tbody>
</table>

B) Survival of HBV+ with tumor size <55 mm

<table>
<thead>
<tr>
<th>Numbers at risk</th>
<th>Time</th>
<th>Percent survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPS3 Mutated</td>
<td>13</td>
<td>100</td>
</tr>
<tr>
<td>TPS3 Wild-type</td>
<td>19</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>20</td>
</tr>
</tbody>
</table>

C) Survival of HBV+ HCC with AFP >24 ng/ml

<table>
<thead>
<tr>
<th>Numbers at risk</th>
<th>Time</th>
<th>Percent survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPS3 Mutated</td>
<td>20</td>
<td>100</td>
</tr>
<tr>
<td>TPS3 Wild-type</td>
<td>24</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>20</td>
</tr>
</tbody>
</table>

D) Survival of HBV+ with tumor size >55 mm

<table>
<thead>
<tr>
<th>Numbers at risk</th>
<th>Time</th>
<th>Percent survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPS3 Mutated</td>
<td>18</td>
<td>100</td>
</tr>
<tr>
<td>TPS3 Wild-type</td>
<td>17</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>20</td>
</tr>
</tbody>
</table>

E) Survival of HBV- HCC with tumor size <55 mm

<table>
<thead>
<tr>
<th>Numbers at risk</th>
<th>Time</th>
<th>Percent survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPS3 Mutated</td>
<td>5</td>
<td>100</td>
</tr>
<tr>
<td>TPS3 Wild-type</td>
<td>36</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>28</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>20</td>
</tr>
</tbody>
</table>

F) Survival of HBV- HCC with tumor size >55 mm

<table>
<thead>
<tr>
<th>Numbers at risk</th>
<th>Time</th>
<th>Percent survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPS3 Mutated</td>
<td>9</td>
<td>100</td>
</tr>
<tr>
<td>TPS3 Wild-type</td>
<td>36</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>22</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>20</td>
</tr>
</tbody>
</table>